Silence Therapeutics reported a Q1 2025 performance characterized by extremely modest topline revenue and a substantial operating loss driven by ongoing research and development investments. Revenue for the quarter stood at USD 142 thousand with a gross profit of USD 88 thousand, yielding a gross margin of approximately 61.97%. The quarter reflects the company’s stage in a capital-intensive biotech model where clinical programs remain in early phases and near-term revenue visibility is limited. The company reported an operating loss of USD 28.41 million and a net loss of USD 28.53 million, translating to an EPS of -0.60. The quarterly cash flow showed meaningful burn in operating activities (-USD 12.31 million) and investing activities (-USD 44.38 million), partially offset by a small financing inflow, culminating in a negative net change in cash of USD 56.44 million for the period. Notably, Silence maintains a robust liquidity footprint with USD 64.9 million in cash and cash equivalents and USD 71.6 million in short-term investments, totaling USD 136.5 million in liquid assets and a net cash position of USD -64.95 million (i.e., net cash). Management commentary on the QQ1 2025 call is not included in the provided data, so quotes and transcript-driven insights could not be incorporated. The balance sheet shows no long-term debt, a favorable current ratio (8.81x), and a substantial cash runway that supports ongoing clinical programs and collaborations. The company continues to advance its core pipeline (e.g., SLN360, SLN124) under partnerships with AstraZeneca, Mallinckrodt, and Hansoh, which remain potential value inflection points if clinical milestones are met.